All In Biotech

NDA 208079 · Primus Pharms

Sernivo

Betamethasone Dipropionate · Topical

Last checked: Nov 20, 2026Latest source record: Sep 26, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2016

Feb 5, 2016

Approved uses

1

Original approval plus efficacy supplements

Registered trials

127

30 Phase 3, 11 recruiting

FAERS reports

6,091

4,072 serious, 503 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 22, 2026.

SERNIVO Spray is indicated for the treatment of mild to moderate plaque psoriasis in patients 18 years of age or older. SERNIVO Spray is a corticosteroid indicated for the treatment of mild to moderate plaque psoriasis in patients 18 years of age or older. ( 1 )

Mechanism: Corticosteroids play a role in cellular signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action of SERNIVO Spray in psoriasis is unknown. 16.1 How Supplied/Storage SERNIVO Spray is a slightly thickened, white to off-white, non-sterile emulsion supplied in high density polyethylene bottles with a heat induction seal lined polypropylene cap. The drug is supplied in the following volumes: 120 mL (NDC 68040-714-28) Store at controlled room temperature of 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F) [ See USP...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • SERNIVO · BETAMETHASONE DIPROPIONATE EQ 0.05% BASE/SPRAY · SPRAY, TOPICAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Betamethasone Dipropionate" as an intervention, any sponsor and status, largest first.

All 127 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,453
  • off label use672
  • macular degeneration532
  • nausea501
  • psoriasis473
  • pruritus468
  • pain451
  • condition aggravated429
  • headache394
  • pain in extremity392
  • rash387
  • fatigue381

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200417
200525
200618
200724
200822
200921
201016
201141
201250
201338
201448
201587
2016167
2017222
2018246
2019354
2020433
2021743
2022738
2023780
2024651
2025756
2026594

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 225 on PubMed

Sponsor: Primus Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.